Trastuzumab deruxtecan recommended for approval in the EU by CHMP for HER2-positive metastatic breast cancer
Recommendation based on positive results from the DESTINY-Breast01 trial, which showed durable responses in patients with previously treated diseaseAstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s trastuzumab deruxtecan has been recommended for conditional marketing authorisation in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens. In Europe, approximately 520,000 cases of breast cancer in women are diagnosed annually, with